Trial Profile
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Melphalan; Thalidomide
- Indications Multiple myeloma; Smoldering multiple myeloma
- Focus Therapeutic Use
- 28 May 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Jun 2020 Planned End Date changed from 1 May 2025 to 1 Dec 2020.
- 12 Jun 2020 Planned primary completion date changed from 1 May 2025 to 1 Dec 2020.